On Monday, Oct. 1, at the Cantor Fitzgerald Global Healthcare Conference Dr. Glickman stated that enrollment for the VOS study was completed and the study was underway.
Based on Aurinia's stellar performance to date, I expect that everything is on schedule and that the study will be completed in December.
It's worth noting that Dr. Glickman also stated that Aurinia is still looking (per plan) at divestiture model, although they may further develop VOS themselves, though action would be after the phase 2 study. He immediately stated that they have sufficiant cash to carry them through Q2 2020, which would cover all their current studies and subsequent drug approval filing.
Milestone's in the next six months - data from VOS study by end of year and FSGS data coming out in next few months with multiple publications.
Here's the link to the webcast from Cantor Fitzgerald site:
News 
Market Data 
Discover 
